Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

OKYO

OKYO Pharma Limited

May 03 • 03:46PM ET

1.53

Dollar change -0.01
Percentage change -0.97	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	27.83%	Shs Outstand	25.52M	Perf Week	4.07%
Market Cap	39.05M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	18.42M	Perf Month	2.00%
Income	-	PEG	-	EPS next Q	-	Inst Own	3.35%	Short Float	0.50%	Perf Quarter	6.25%
Sales	-	P/S	-	EPS this Y	34.43%	Inst Trans	-	Short Ratio	0.54	Perf Half Y	-4.38%
Book/sh	-	P/B	-	EPS next Y	5.00%	ROA	-	Short Interest	0.09M	Perf Year	-7.27%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.92 - 3.25	Perf YTD	-13.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-53.58%	ROI	-	52W High	-52.92%	Beta	0.04
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	0.00%	Gross Margin	-	52W Low	66.29%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	57.83	Volatility	4.73% 6.49%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-39.29%	Payout	-	Rel Volume	0.06	Prev Close	1.54
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	170.45K	Price	1.53
SMA20	7.60%	SMA50	5.46%	SMA200	-7.84%	Trades		Volume	9,850	Change	-0.97%

Apr-30-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) (GlobeNewswire)
Apr-08-24 07:00PM	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 (GlobeNewswire)
Apr-02-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery (GlobeNewswire)
Mar-22-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 (GlobeNewswire) -12.78%
Mar-21-24 07:00AM	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial (GlobeNewswire)
07:00AM	Loading…
Mar-20-24 07:00AM	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event (GlobeNewswire) +20.00%
Feb-09-24 07:00AM	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain (GlobeNewswire) +19.58%
Jan-31-24 07:00AM	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board (GlobeNewswire)
Jan-08-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease (GlobeNewswire)
Jan-05-24 09:30AM	OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire) +9.65%
Dec-04-23 07:00AM	OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit (GlobeNewswire)
Oct-31-23 07:00AM	OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction (GlobeNewswire)
Oct-09-23 07:00AM	OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP) (GlobeNewswire) -10.62%
Oct-05-23 07:00AM	OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ('DED') (GlobeNewswire) -9.09%
Sep-15-23 07:00AM	OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +12.43%
09:15AM	Loading…
Sep-14-23 09:15AM	OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) -10.61%
08:45AM	OKYO Pharma Limited Announces Withdrawal of Public Offering (GlobeNewswire)
Sep-13-23 04:05PM	OKYO Pharma Announces Public Offering of Ordinary Shares (GlobeNewswire)
Sep-08-23 07:00AM	OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (GlobeNewswire)
Aug-30-23 07:00AM	OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (DED) (GlobeNewswire) -17.76%
Aug-29-23 07:00AM	OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule (GlobeNewswire) +8.60%
Aug-15-23 09:00AM	OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023 (GlobeNewswire)
Jul-31-23 02:18AM	OKYO Pharma Limited Announces Withdrawal of Public Offering (GlobeNewswire) -15.00%
Jul-28-23 05:25PM	OKYO Pharma Announces Proposed Public Offering of Ordinary Shares (GlobeNewswire) +17.02%
05:05PM	OKYO Pharma Limited Receives Nasdaq Deficiency Notice (GlobeNewswire)
07:01AM	OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center (GlobeNewswire)
Jul-27-23 11:30AM	OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer (GlobeNewswire) +23.28%
Jun-06-23 09:30AM	OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease (GlobeNewswire) -16.57%
May-11-23 07:00AM	OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform (GlobeNewswire) -11.76%
May-09-23 08:45AM	Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited (ACCESSWIRE) -8.92%
01:22PM	Loading…
May-04-23 01:22PM	OKYO Pharma reaches milestone with first patient screening for dry eye disease trial (News Direct) +6.06%
May-03-23 02:00AM	OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023 (GlobeNewswire) +6.45%
May-02-23 02:00AM	OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease (GlobeNewswire) +9.93%
Apr-25-23 02:00AM	OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease (GlobeNewswire) -6.57%
Apr-18-23 10:00AM	OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay (ACCESSWIRE)

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BRANCACCIO JOHN P	Director	Sep 15 '23	Buy	1.50	16,670	25,005	16,670	Sep 28 06:15 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OKYO

OKYO Pharma Limited

Upgrade your FINVIZ experience